Cargando…

凝血与纤溶标志物在肺癌血栓栓塞患者中的临床应用价值研究

BACKGROUND AND OBJECTIVE: Coagulation and fibrinolysis biomarkers can effectively reflect the dysfunction of coagulation and anticoagulation system, and the changes of their levels were closely related to the hypercoagulable status. The aim of this study is to study the variation tendency of these c...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105356/
https://www.ncbi.nlm.nih.gov/pubmed/30172264
http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.03
_version_ 1783349646685372416
collection PubMed
description BACKGROUND AND OBJECTIVE: Coagulation and fibrinolysis biomarkers can effectively reflect the dysfunction of coagulation and anticoagulation system, and the changes of their levels were closely related to the hypercoagulable status. The aim of this study is to study the variation tendency of these coagulation and fibrinolysis markers and explore the diagnosis power and clinical value of these biomarker for thrombosis in postoperative lung cancer patients with deep vein catheterization. METHODS: We selected 118 postoperative lung cancer patients with deep vein catheterization including 29 patients with thromboembolism and 89 patients in control group. Coagulation and fibrinolysis parameters [thrombomodulin (TM)/thrombin-antithrombin complex (TAT)/α2-plasmin inhibitor-plasmin complexes (PIC)/tissue plasminogen activator-inhibitor complexes (t-PAIC)] and traditional coagulation time[prothrombintime (PT)/activated partial thrombo plastin time(APTT)/thrombintime (TT)/fibrinogen (FIB)/antithrombin Ⅲ (ATIII)/fibrinogen degradation products (FDP)/D-Dimer (D-D)] were detected in both groups. We analyzed the variation tendency of these biomarkers and figured out the diagnosis powerfor thrombosis. RESULTS: A statistically significant difference was available on the value of TM, TAT, PIC, t-PAIC, D-D, FDP between thrombosis group and non-thrombosis group (P < 0.05). TM, TAT, PIC, t-PAIC, D-D, FDP performed with an AUC of 0.770, 0.771, 0.669, 0.671, 0.819, 0.816, respectively (P < 0.05). CONCLUSION: An enhanced coagulation and fibrinolysis activity existed in lung cancer patients with deep vein catheterization after surgery, and early detection of coagulation and fibrinolytic biomarkers could prevent thrombosis and reduce postoperative thrombosis complications in patients with lung cancer.
format Online
Article
Text
id pubmed-6105356
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-61053562018-08-27 凝血与纤溶标志物在肺癌血栓栓塞患者中的临床应用价值研究 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Coagulation and fibrinolysis biomarkers can effectively reflect the dysfunction of coagulation and anticoagulation system, and the changes of their levels were closely related to the hypercoagulable status. The aim of this study is to study the variation tendency of these coagulation and fibrinolysis markers and explore the diagnosis power and clinical value of these biomarker for thrombosis in postoperative lung cancer patients with deep vein catheterization. METHODS: We selected 118 postoperative lung cancer patients with deep vein catheterization including 29 patients with thromboembolism and 89 patients in control group. Coagulation and fibrinolysis parameters [thrombomodulin (TM)/thrombin-antithrombin complex (TAT)/α2-plasmin inhibitor-plasmin complexes (PIC)/tissue plasminogen activator-inhibitor complexes (t-PAIC)] and traditional coagulation time[prothrombintime (PT)/activated partial thrombo plastin time(APTT)/thrombintime (TT)/fibrinogen (FIB)/antithrombin Ⅲ (ATIII)/fibrinogen degradation products (FDP)/D-Dimer (D-D)] were detected in both groups. We analyzed the variation tendency of these biomarkers and figured out the diagnosis powerfor thrombosis. RESULTS: A statistically significant difference was available on the value of TM, TAT, PIC, t-PAIC, D-D, FDP between thrombosis group and non-thrombosis group (P < 0.05). TM, TAT, PIC, t-PAIC, D-D, FDP performed with an AUC of 0.770, 0.771, 0.669, 0.671, 0.819, 0.816, respectively (P < 0.05). CONCLUSION: An enhanced coagulation and fibrinolysis activity existed in lung cancer patients with deep vein catheterization after surgery, and early detection of coagulation and fibrinolytic biomarkers could prevent thrombosis and reduce postoperative thrombosis complications in patients with lung cancer. 中国肺癌杂志编辑部 2018-08-20 /pmc/articles/PMC6105356/ /pubmed/30172264 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.03 Text en 版权所有©《中国肺癌杂志》编辑部2018 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
凝血与纤溶标志物在肺癌血栓栓塞患者中的临床应用价值研究
title 凝血与纤溶标志物在肺癌血栓栓塞患者中的临床应用价值研究
title_full 凝血与纤溶标志物在肺癌血栓栓塞患者中的临床应用价值研究
title_fullStr 凝血与纤溶标志物在肺癌血栓栓塞患者中的临床应用价值研究
title_full_unstemmed 凝血与纤溶标志物在肺癌血栓栓塞患者中的临床应用价值研究
title_short 凝血与纤溶标志物在肺癌血栓栓塞患者中的临床应用价值研究
title_sort 凝血与纤溶标志物在肺癌血栓栓塞患者中的临床应用价值研究
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105356/
https://www.ncbi.nlm.nih.gov/pubmed/30172264
http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.03
work_keys_str_mv AT níngxuèyǔxiānróngbiāozhìwùzàifèiáixuèshuānshuānsāihuànzhězhōngdelínchuángyīngyòngjiàzhíyánjiū
AT níngxuèyǔxiānróngbiāozhìwùzàifèiáixuèshuānshuānsāihuànzhězhōngdelínchuángyīngyòngjiàzhíyánjiū
AT níngxuèyǔxiānróngbiāozhìwùzàifèiáixuèshuānshuānsāihuànzhězhōngdelínchuángyīngyòngjiàzhíyánjiū
AT níngxuèyǔxiānróngbiāozhìwùzàifèiáixuèshuānshuānsāihuànzhězhōngdelínchuángyīngyòngjiàzhíyánjiū